Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trial
National Institute of Allergy and Infectious Diseases, National Institute of Mental Health, National Institute on Drug Abuse, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, ViiV Healthcare, and The Bill & Melinda Gates Foundation.
Authors
- Nyaradzo Mgodi (ORCID: https://orcid.org/0000-0002-3085-5259)
- E.L. Hamilton
- Bekezela Siziba (ORCID: https://orcid.org/0009-0007-3495-4207)
- R P Choudhury
- Julie Ngo (ORCID: https://orcid.org/0000-0002-1979-3931)
- Adeola Adeyeye (ORCID: https://orcid.org/0000-0002-3677-6068)
- Ishana Naidoo
- Yuqing Jiao
- Hans Spiegel (ORCID: https://orcid.org/0000-0001-9552-789X)
- Sybil Hosek (ORCID: https://orcid.org/0000-0001-5230-0759)
- Lynda Stranix‐Chibanda (ORCID: https://orcid.org/0000-0003-3566-1688)
- Betty Kamira
- Yaw Agyei (ORCID: https://orcid.org/0000-0001-5614-4108)
- Sinéad Delany‐Moretlwe (ORCID: https://orcid.org/0000-0003-0376-1019)
- Mark A. Marzinke (ORCID: https://orcid.org/0000-0003-1670-8786)
- Brett Hanscom (ORCID: https://orcid.org/0000-0003-0618-2979)
- Brenda Gati Mirembe (ORCID: https://orcid.org/0000-0001-9074-6751)
- Cynthia McCoig
- Estelle Piwowar-Manning
Institutions
- Family Health International 360 (US)
- Johns Hopkins University (US)
- University of Zimbabwe (ZW)
- ViiV Healthcare (Spain) (ES)
- University of the Witwatersrand (ZA)
- University of Illinois Chicago (US)
- Fred Hutch Cancer Center (US)
- MUJHU Research Collaboration (UG)
- National Institute of Allergy and Infectious Diseases (US)
- Kelly Services (United States) (US)
Publication Details
- Journal
- The Lancet HIV
- Published
- 2025-03-12
- DOI
- https://doi.org/10.1016/s2352-3018(24)00310-2
- Citations
- 4
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 5.58
Funders
- Bill and Melinda Gates Foundation
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- ViiV Healthcare